A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2期
已完成
NCT05613088
| 适应症 | Neoplasms, Ovarian |
|---|
| 分期 | 2期 |
|---|
| 申办方 | Bristol-Myers Squibb |
|---|
| 状态 | 已完成 |
|---|
| 受试者人数 | 106 人 |
|---|
| 干预（药物） | MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD), Topotecan |
|---|
| 开始日期 | 2023年2月1日 |
|---|
| 完成日期 | 2024年6月17日 |
|---|
| 结果公布日 | 2025年7月3日 |
|---|
摘要
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS ovarian, primary peritoneal, or fallopian tube cancer.
Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment
From the date of randomization to the date of first objectively-documented progression or the date of subsequent therapy (Up to approximately 70 weeks) · Percent of participants
| MORAb-202 | 20.0 Percent of participants |
|---|
| Investigator's Choice (IC) Chemotherapy | 13.9 Percent of participants |
|---|
Number of Participants With Treatment-Related Adverse Event (TRAEs) Leading to Discontinuation Within 6 Months From First Dose
From first dose of study medication up to 6 months · Participants
| MORAb-202 | 2 Participants |
|---|
| Investigator's Choice (IC) Chemotherapy | 0 Participants |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。